Chemotherapy of advanced prostatic carcinoma with cyclophosphamide or 5-fluorouracil: results of first national randomized study.
The National Prostatic Cancer Project has randomized this study for endocrine-resistant prostatic cancer patients for treatment with standard hormonal or other therapies compared to 5-fluorouracil and cyclophosphamide. Both agents were found at the probability level of 0.05 to have a significant advantage over standard treatment in terms of objective response, subjective improvement and minimal toxicity. Additional chemotherapy protocols are currently under way. This randomized trial is the first report of such a national study completed to date. We are much encouraged by this program and believe that additional agents now under consideration will provide additionally encouraging results.
D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D003520:Cyclophosphamide; D005472:Fluorouracil